GlassScriptPhysician profile
Frank P Lorusso
NPI 1952496457
$1,917.90
in general payments reported to CMS, 2019-2025
28 companies · $446 in 2025
The $446 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $144 · 2021: $333 · 2022: $361 · 2023: $212 · 2024: $228 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.78 | 2020-2025 | |
| Pfizer INC. | $121.65 | 2022-2025 | |
| Astellas Pharma US INC | $119.93 | 2019-2025 | Veozah |
| Sage Therapeutics, LLC | $117.64 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $104.71 | 2024-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $82.39 | 2019-2025 | Gardasil 9 |
| Coopersurgical, INC. | $74.98 | 2023-2025 | Mara Console, Paragard T 380a |
| Therapeuticsmd, INC. | $63.85 | 2019-2021 | |
| Hologic Sales and Service, LLC | $63.67 | 2021-2025 | Aptima |
| Channel Medsystems, INC. | $63.04 | 2021-2023 | |
| Ibsa Pharma INC. | $48.11 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.66 | 2021-2025 | Xifaxan |
| Amag Pharmaceuticals, INC. | $39.52 | 2019 | |
| Pharmacosmos Therapeutics INC. | $39.05 | 2025 | Monoferric |
| Roche Diagnostics Corporation | $37.78 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $35.97 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.97 | 2019-2024 | |
| Organon LLC | $25.02 | 2023 | Nexplanon |
| Pacira Pharmaceuticals Incorporated | $22.49 | 2025 | Exparel |
| Baxter Healthcare | $21.76 | 2024 | Perclot |
| Allergan, INC. | $18.86 | 2020 | |
| Kaleo, INC. | $16.45 | 2021 | |
| Adlon Therapeutics L.P. | $14.76 | 2021 | |
| Minerva Surgical, INC | $14.51 | 2022 | |
| Ethicon US, LLC | $14.45 | 2021 | |
| Olympus America INC. | $13.46 | 2021 | |
| Myovant Sciences INC. | $12.78 | 2022 | |
| Smith+Nephew, INC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Lorusso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.